My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Ravoxertinib (GDC-0994; RG-7842)
    Ravoxertinib (GDC-0994; RG-7842)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0466
    CAS #: 1453848-26-4 Purity ≥98%

    Description: Ravoxertinib (also known as GDC0994; RG7842) is a novel, potent, orally bioavailable inhibitor of extracellular signal-regulated kinase (ERK1/2) with potential antineoplastic activity. It inhibits ERK1/2 with IC50s of 1.1 nM and 0.3 nM, respectively. It demonstrates high anti-proliferative activity in vitro and in vivo antitumor efficacy as well.

    References: J Med Chem. 2016 Jun 23;59(12):5650-60.

    Related CAS: 2070009-58-2 (HCl)

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)439.85
    FormulaC21H18ClFN6O2
    CAS No.1453848-26-4
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 87 mg/mL (197.8 mM)
    Water: <1 mg/mL
    Ethanol: 87 mg/mL (197.8 mM)
    Solubility (In vivo)2% DMSO+30% PEG 300+5% Tween 80+ddH2O: 30 mg/mL
    Synonyms

    RG7842; GDC-0994; RG 7842; GDC 0994; GDC0994;RG-7842;

    Chemical Name: (S)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one

    InChi Key: RZUOCXOYPYGSKL-GOSISDBHSA-N

    InChi Code: InChI=1S/C21H18ClFN6O2/c1-28-19(5-8-25-28)27-21-24-7-4-17(26-21)13-6-9-29(20(31)11-13)18(12-30)14-2-3-15(22)16(23)10-14/h2-11,18,30H,12H2,1H3,(H,24,26,27)/t18-/m1/s1

    SMILES Code: O=C1C=C(C2=NC(NC3=CC=NN3C)=NC=C2)C=CN1[[email protected]@H](C4=CC=C(Cl)C(F)=C4)CO 



    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: GDC-0994, also known as ravoxertinib and RG7842, is a potent, orally available ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. It has demonstrated anticancer activity. Upon oral administration, GDC-0994 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways. This prevents ERK-dependent tumor cell proliferation and survival. 


    Kinase Assay: Ravoxertinib (GDC-0994) is an orally bioavailable ERK kinase inhibitor with an IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively. Ravoxertinib (GDC-0994) also inhibits p90RSK with an IC50 of 12 nM. Ravoxertinib (GDC-0994) is highly selective for ERK1 and ERK2, with biochemical potency of 1.1 nM and 0.3 nM, respectively.


    Cell Assay: GDC-0994 potently inhibits phospho-p90RSK in tumor cells.

    In VivoGDC-0994 (p.o.) results in significant single-agent activity in multiple in vivo cancer models, including KRAS-mutant and BRAF-mutant human xenograft tumors in mice. In vivo, GDC-0994 (p.o.) inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways, and subsequently prevents ERK-dependent tumor cell proliferation and survival.
    Animal modelPK/PD data for Ravoxertinib (GDC-0994) in the HCT116 mouse xenograft model. HCT116 tumors are established in nude mice to a tumor volume of 400-600 mm3. Mice are treated with a single oral dose of 22 at 15, 30, or 100 mg/kg versus vehicle control alone (40% PEG400/60% (10% HPβCD)) follow by tumor and plasma collection at 2, 8, 16, and 24 h postdose. Tumor levels of phosphorylated p90RSK (pRSK) relative total p90RSK (tRSK) are measured by quantitative Western blot and are normalized to vehicle control at 2 h postdose (set to 100%). Plasma and tumor concentrations are measured by LC−MS.
    Formulation & DosageDissolved in 40% PEG400/60% (10% HPβCD); 15, 30, or 100 mg/kg; oral
    ReferencesJ Med Chem. 2016 Jun 23;59(12):5650-60.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    GDC-0994 (Ravoxertinib)

    UV traces from incubation of 6 with hepatocytes at t = 3 h (M3 = compound 7): h = human, m = mouse, r = rat, d = dog, c = cynomolgus monkey.

    GDC-0994 (Ravoxertinib)

    Compound exposure vs time in a multidose mouse PK study with compound 22, formulated in 40% PEG400/60% (10% HPβCD) water.  2016 Jun 23;59(12):5650-60.

    GDC-0994 (Ravoxertinib)

    Crystal structures of 22 bound to ERK2 (brown) and CDK2 (purple): (A) compound 22 bound to ERK2; (B) superposition of ERK2 and CDK2 cocrystal structures with compound 22. Red dotted lines indicate hydrogen bonds. Red spheres indicate water molecules.


    GDC-0994 (Ravoxertinib)

    HCT116 study PK/PD analysis with compound 22: PK/PD data for 22 in the HCT116 mouse xenograft model.   2016 Jun 23;59(12):5650-60.

    GDC-0994 (Ravoxertinib)

    Activity of 22 against 279 kinases at 1 μM. Illustration reproduced courtesy of Cell Signaling Technology.


    GDC-0994 (Ravoxertinib)

    HCT116 mouse xenograft data with compound 22.  2016 Jun 23;59(12):5650-60.


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?